| Literature DB >> 27189269 |
Aida Serra1, Xavier Gallart-Palau1, Rachel Su-En See-Toh1, Xinya Hemu1, James P Tam1, Siu Kwan Sze1.
Abstract
Nutraceuticals have been proposed to exert positive effects on human health and confer protection against many chronic diseases. A major bioactive component of soy-based foods is lunasin peptide, which has potential to exert a major impact on the health of human consumers worldwide, but the biochemical features of dietary lunasin still remain poorly characterized. In this study, lunasin was purified from a soy-based food product via strong anion exchange solid phase extraction and then subjected to top-down mass spectrometry analysis that revealed in detail the molecular diversity of lunasin in processed soybean foods. We detected multiple glycated proteoforms together with potentially toxic advanced glycation end products (AGEs) derived from lunasin. In both cases, modification sites were Lys24 and Lys29 located at the helical region that shows structural homology with a conserved region of chromatin-binding proteins. The identified post-translational modifications may have an important repercussion on lunasin epigenetic regulatory capacity. Taking together, our results demonstrate the importance of proper chemical characterization of commercial processed food products to assess their impact on consumer's health and risk of chronic diseases.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27189269 PMCID: PMC4870627 DOI: 10.1038/srep26106
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Analysis of soybean product extract by linear-mode MALDI-TOF MS.
(A) Spectrum of raw soybean extract. No peaks were detected in the 5000–6000 m/z mass range. (B) Spectrum of commercial soybean beverage powder extract. Multiple peaks with laddering mass-shift of 162.05 Da were identified in 5000–6000 m/z. (C) Lunasin-containing fractions obtained by reversed-phase high-performance liquid chromatography (RP-HPLC). (D) Spectrum of purified lunasin obtained by strong anion exchange solid phase extraction (SAX-SPE).
Figure 2Optimization of the elution step for lunasin purification by strong anion exchange solid phase extraction (SAX-SPE).
MALDI-MS spectra of samples eluted sequentially using varying concentrations of salt (100–500 mM NaCl, 150 mM Tris-HCl). Lunasin and its modified variants were completely eluted at 100 mM NaCl, 150 mM Tris-HCl.
Figure 3Lunasin characterization by top-down mass spectrometry.
(A) HCD spectrum of unmodified lunasin. (B) ETD spectrum of unmodified lunasin (lacking z-type ions due to the presence of the poly-Asp-carboxyl tail).
Figure 4Characterization of glycated lunasin by top-down MS.
HCD spectrum of single glycated lunasin with a mass addition of 162.05 Da at Lys24.
Figure 5Deconvoluted full-MS spectra including all peptides detected in the mass range 5000–6000 m/z.
Proteoforms of lunasin identified in the commercial soybean beverage powder.
| Peptide | −10logP | Mass | ppm | m/z | z | #Spec | Side chain modifications |
|---|---|---|---|---|---|---|---|
| SKWQHQQDS | 200.00 | 5225.36 | −2.3 | 747.4854 | 7 | 220 | EA |
| SKWQHQQDS | 166.07 | 2098.05 | 0.1 | 525.5196 | 4 | 2 | EA |
| KWQHQQDS | 124.41 | 5138.33 | −0.7 | 857.3945 | 6 | 10 | EA |
| GVNLTP | 112.91 | 3301.41 | −2.7 | 826.3575 | 4 | 56 | EA |
| LQGVNLTP | 112.08 | 3542.55 | −1.2 | 886.6443 | 4 | 11 | EA |
| DS | 100.86 | 4302.92 | 0.8 | 861.5914 | 5 | 12 | EA |
| SKWQHQQDS | 92.20 | 2098.05 | 0.1 | 525.5196 | 4 | 2 | EA |
| 76.18 | 4807.13 | −5.1 | 962.4275 | 5 | 4 | Pyro-Glutamate conversion (N-term Gln); EA | |
| SKWQHQQDS | 75.56 | 5241.35 | −2 | 874.5645 | 6 | 38 | EA; Oxidation (Met) |
| SKWQHQQDS | 59.40 | 5387.41 | −2.4 | 898.907 | 6 | 5 | EA; Hex (Lys) |
| SKWQHQQDS | 58.47 | 5267.37 | 3 | 878.9047 | 6 | 5 | EA; Acetylation (Lys) |
| WQHQQDS | 55.05 | 5010.23 | −0.2 | 1003.053 | 5 | 1 | EA |
| SKWQHQQDS | 54.48 | 5257.35 | −1.3 | 877.2308 | 6 | 14 | EA; Dihydroxy (Lys) |
| SKWQHQQDS | 53.17 | 5208.33 | 5.7 | 869.0676 | 6 | 2 | EA; Dehydration (Asp); Deamidation (Asn) |
| SKWQHQQDS | 52.19 | 5549.46 | −2.3 | 925.9158 | 6 | 2 | EA; Di-Hex (Lys) |
| SKWQHQQDS | 52.01 | 5240.36 | −1.9 | 874.3986 | 6 | 4 | EA; Deamidation (Gln); Methyl ester (Asp) |
| SKWQHQQDS | 49.76 | 5387.41 | −1.6 | 898.9077 | 6 | 25 | EA; Hex (Lys) |
| GVNLTP | 48.69 | 3344.42 | 5.9 | 837.1161 | 4 | 1 | EA; Carbamylation (Lys) |
| GVNLTP | 48.53 | 3463.46 | −0.9 | 866.8721 | 4 | 2 | EA; Hex (Lys) |
| SKWQHQQDS | 46.34 | 5207.35 | −0.1 | 868.8985 | 6 | 2 | EA; Dehydration (Asn) |
| GVNLTP | 45.05 | 3463.46 | −0.4 | 866.8726 | 4 | 2 | EA; Hex (Lys) |
| SKWQHQQDS | 44.53 | 5268.36 | 5.2 | 879.0725 | 6 | 1 | EA; Carbamylation (Lys) |
| SKWQHQQDS | 43.02 | 5226.34 | 1.1 | 872.0652 | 6 | 3 | EA; Deamidation (Gln) |
| SKWQHQQDS | 41.85 | 5403.41 | −0.2 | 901.5748 | 6 | 2 | EA; Galactosyl hydroxylysine (Lys) |
| SKWQHQQDS | 40.76 | 5207.35 | −4.1 | 868.895 | 6 | 3 | EA; Dehydration (Asp) |
| SKWQHQQDS | 39.34 | 5256.35 | −0.2 | 877.0659 | 6 | 1 | EA; Oxidation (Met); Deamidation (Gln); Methyl ester (Asp) |
| SKWQHQQDS | 38.98 | 5711.52 | −3.6 | 952.9233 | 6 | 1 | EA; Tri-Hex (Lys) |
| SKWQHQQDS | 37.42 | 5565.46 | −2.2 | 928.5817 | 6 | 2 | EA; Glucosylgalactosyl hydroxylysine (Lys) |
| SKWQHQQDS | 36.08 | 5257.35 | −4.4 | 877.2281 | 6 | 1 | EA; Dihydroxy (Arg) |
| KWQHQQDS | 30.45 | 5154.32 | −5.4 | 860.0562 | 6 | 1 | EA; Oxidation (Met) |
| GVNLTP | 29.98 | 3302.39 | 4.2 | 826.6092 | 4 | 2 | EA; Deamidation (Asn) |
Sequences have been identified using 2S albumin pre-protein sequence as database. PTM has been further validated manually.
a−10logP, p-value was converted from the linear discriminative function score by the PEAKS PTM software. A higher −10logP value indicated a more confident identification.
b#Spec, number of spectrums for each peptide is the result of the sum of all the spectrums identified considering all replicates.
cEA, means Cys-to-pseudoLys derivatized Cys.
Advanced glycation end products (AGEs) and glycated proteoforms derived from lunasin identified in the two different batch of commercial soybean beverage powder.
| Batch | Peptide | − 10logP | Mass | ppm | m/z | z | #Spec | Side chain modifications | |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Glycation | ||||||||
| SKWQHQQDS | 59.40 | 5387.41 | −2.4 | 898.9070 | 6 | 5 | EA | ||
| SKWQHQQDS | 28.05 | 5549.46 | −1.9 | 925.9161 | 6 | 1 | EA; Di-Hex (Lys24) | ||
| SKWQHQQDS | 49.76 | 5387.41 | −1.6 | 898.9077 | 6 | 16 | EA; Hex (Lys29) | ||
| SKWQHQQDS | 38.98 | 5711.52 | −3.6 | 952.9233 | 6 | 1 | EA; Tri-Hex (Lys29) | ||
| AGEs | |||||||||
| SKWQHQQDS | 200.00 | 5241.34 | 0.1 | 874.5645 | 6 | 37 | EA; CEL (Lys24); CML (Lys29) | ||
| SKWQHQQDS | 90.21 | 5241.34 | 0.1 | 874.5645 | 6 | 16 | EA; CML (Lys24); CEL (Lys29) | ||
| KWQHQQDS | 81.25 | 5154.31 | −3.3 | 860.0562 | 6 | 2 | EA; CEL (Lys24); CML (Lys29) | ||
| SKWQHQQDS | 45.57 | 5255.36 | −3.1 | 876.8976 | 6 | 3 | EA; CEL(Lys24, 29) | ||
| SKWQHQQDS | 39.28 | 5283.36 | 3.3 | 881.5708 | 6 | 2 | EA; CML (Lys 29) | ||
| SKWQHQQDS | 43.46 | 5369.40 | 0.1 | 895.9075 | 6 | 1 | EA; CEL(Lys24, 29) | ||
| 2 | Glycation | ||||||||
| SKWQHQQDS | 63.26 | 5387.41 | −2.4 | 898.9070 | 6 | 5 | EA; Hex (Lys24) | ||
| SKWQHQQDS | 52.19 | 5549.46 | −2.3 | 925.9158 | 6 | 2 | EA; Di-Hex (Lys24) | ||
| GVNLTP | 49.05 | 3463.46 | −0.9 | 866.8721 | 4 | 2 | EA; Hex (Lys24) | ||
| GVNLTP | 48.58 | 3463.46 | −0.4 | 866.8726 | 4 | 2 | EA; Hex (Lys29) | ||
| SKWQHQQDS | 38.74 | 5711.52 | −3.6 | 952.9233 | 6 | 1 | EA; Tri-Hex (Lys29) | ||
| AGEs | |||||||||
| SKWQHQQDS | 147.04 | 5241.34 | 1.5 | 874.5645 | 6 | 9 | EA; CEL (Lys24); CML (Lys29) | ||
| SKWQHQQDS | 133.77 | 5241.34 | 3.3 | 874.5645 | 6 | 1 | EA; CML (Lys24); CEL (Lys29) | ||
Two different units of product bought in a three month interval were processed per separate (refered as batch 1 and 2). PTM has been further validated manually. PTM modification site for non-full sequence peptides is considered based on the position of the amino acid in the full sequence of the peptide.
a−10logP, p-value was converted from the linear discriminative function score by the PEAKS PTM software. A higher −10logP value indicated a more confident identification.
b#Spec, number of spectrums for each peptide is the result of the sum of all the spectrums identified considering all replicates.
cEA, means Cys-to-pseudoLys derivatized Cys.
Figure 6Glycated/glycoxidated modification sites in lunasin sequence.
(A) Occurrence of glycation and glycoxidation at the four Lys present in lunasin sequence. N.D. means not detected. (B) Description of distinct features present in lunasin sequence and localization of glycated/glycoxidated sites. Modified Lys residues (underlined in red) are both located at the chromatin-binding protein homologous region of lunasin (shaded in blue). (C) Analysis of the diversity of glycation and glycoxidation species detected at the residues Lys 24 and Lys 29. Distribution was calculated considering both analyzed batch and based on total spectral counts.
Quantitative study of glycated and glycoxidated lunasin present in commercial soybean beverage powder.
| Lunasin proteoforms | |||
|---|---|---|---|
| Non-modified (mg) | Glycated (μg) | AGEs (μg) | |
| Batch 1 | 0.23 | 27.1 | 183.7 |
| Batch 2 | 0.22 | 38.8 | 68.9 |
Quantification was performed in two different batch of commercial soybean beverage powder based on spectral counts.